Change in Liver Size and Fat Content after Treatment with Optifast&lt;SUP&gt;®&lt;/SUP&gt; Very Low Calorie Diet

Lewis, Mark; Phillips, Madeleine L; Slavotinek, John; Kow, Lilian; Thompson, Campbell; Toouli, Jim

doi:10.1381/096089206777346682

Cited by 199 publications

(118 citation statements)

References 19 publications

Supporting

Mentioning

105

Contrasting

Unclassified

Order By: Relevance

“…(2) We began the use of Optifast in January 2012 as a treatment strategy for potential donors with radiological or histopathological evidence of hepatic steatosis. We provide a retrospective review of the efficacy and safety of this agent in converting steatotic donors into suitable candidates for living donor liver transplantation.…”

Section: To the Editormentioning

confidence: 99%

Treatment with Optifast reduces hepatic steatosis and increases candidacy rates for living donor liver transplantation

et al. 2016

View full text Add to dashboard Cite

Section: To the Editormentioning

confidence: 99%

Treatment with Optifast reduces hepatic steatosis and increases candidacy rates for living donor liver transplantation

et al. 2016

View full text Add to dashboard Cite

“…It is thought that this potential bias is acceptable clinically, as review of the literature shows that as a response mechanism, the liver often increases and decreases in size well past 3.4%. [10,[28][29][30] Liver volume assessed 3-4 weeks post portal vein embolisation shows an increase in volume of 5% being associated with improved patient outcomes. [8] Lewis et al 2006 [10] found liver volume reduced by 14% over a six week period following the implementation of a low calorie diet.…”

Section: Discussionmentioning

confidence: 99%

“…[10,[28][29][30] Liver volume assessed 3-4 weeks post portal vein embolisation shows an increase in volume of 5% being associated with improved patient outcomes. [8] Lewis et al 2006 [10] found liver volume reduced by 14% over a six week period following the implementation of a low calorie diet. Edholm et al 2014 [28] showed an average decrease in liver size of 18% in ten female participants following two weeks on a low calorie diet.…”

Section: Discussionmentioning

confidence: 99%

“…[9] Liver volume is also commonly assessed six weeks and one week prior to gastric banding surgery to ensure adequate volume reduction. [10] Computed Tomography (CT) is currently considered the gold standard for assessment of the volume of the adult liver. [11] Magnetic Resonance Imaging (MRI) has also been shown to be accurate in taking volume measurements of the liver.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Computed tomography volume measurements of the liver using a liver segmentation and analysis package: an intra- and inter-rater reliability study

Childs

Thoirs

Esterman

2015

JBGC

View full text Add to dashboard Cite

Introduction: Recent advances in technology have seen the introduction of software assisted image post-processing (SAIP) tools to calculate the volume of the liver from Computed Tomography (CT) images. One such SAIP tool is the semi-automated Philips liver segmentation and analysis package (Endhoven, The Netherlands). The intra-and inter-rater reliability of the liver volumes of 16 participants calculated using this tool was assessed. Methods: Two CT Technologists accessed Abdominal CT data sets and calculated the volume of the liver using the Philips liver segmentation and analysis package. One technologist repeated their calculation. Results: Results demonstrated high intra-rater reliability (ICC 0.9997) and high inter-rater reliability (ICC 0.99994). Analysis with Bland Altman plots showed the mean bias for both intra-and inter-rater reliability to be close to zero with acceptable limits of agreement. Conclusions: This study has shown that liver volume measurements using the Philips SAIP (Endhoven, The Netherlands) can be taken reliably by CT technologists, with confidence that the same results would be obtained between different CT technologists.

show abstract

“…A 10% loss in body weight (10% TWL) will translate into a reduction of visceral, central and abdominal fat, as well as of liver size (12,13); there will be an improvement in associated comorbidities (4,14) and mortality (15).…”

Section: Obesity (Bmi ≥ 30 Kg/mmentioning

confidence: 99%

Usefulness of an intra-gastric balloon before bariatric surgery

et al. 2017

View full text Add to dashboard Cite

Introduction: There are only few reports regarding the use of intragastric-balloons (IGB ® ) to achieve weight loss and subsequently decrease surgical complications. In this study, we try to assess whether presurgery weight loss using IGB decreases the postsurgical mortality after bariatric surgery.Material and methods: This is a prospective case-control study. We matched 1:1 by gender, age (± 10 y-o) and type of surgery (sleeve resection [LSG] or gastric bypass [LGBP]), matching cases (A) and controls (H, from a historic cohort). Morbidly obese patients with an indication for bariatric surgery were included in the study. Cases (A) were recruited from an ongoing clinical trial, and the controls (H) came from a historic cohort prior to the start of the clinic trial. The presurgical weight loss in group A was reached by IGB combined with diet, versus only diet in group H.Results: We included 58 patients, 65.5% women, 69% LGBP/31% LSG. The mean age of group A was 42 and 43.4 years old for group H. ASA III of 24.1% group A vs 58.6% group H, p = 0.012. The mean total weight loss (TWL) before surgery was greater in group A (16.2 kg, SD 9.75) than in group H (1.2 kg, SD 6.4), p < 0.0001. The % of EWL before surgery was 23.5 (SD 11.6) in group A vs 2.4 (SD 8) in group H, p < 0.001. Hospital stay was seven days for group A, and eight days for group H, p = 0.285. The rate of unsuccessful IGB treatment to accomplish the scheduled weight loss was 34.5%. The balloon morbidity was 17.2% (6.9% severe). All in all, morbidity (due to bariatric surgery and IGB) was 41% in both groups. Postsurgical morbidity moderate-severe was 20.3% in group A (6.9% severe) and 27.3% in group H (17.2% severe) without statistical significance. One patient died in group H (mortality rate, 3.44%).Conclusion: Preoperative IGB treatment in morbid obesity has not been found to be effective at decreasing postsurgical morbidity LSG and LGBP, despite the fact that it acheives a greater weight loss than diet and exercise.

show abstract

Change in Liver Size and Fat Content after Treatment with Optifast<SUP>®</SUP> Very Low Calorie Diet

Cited by 199 publications

References 19 publications

Treatment with Optifast reduces hepatic steatosis and increases candidacy rates for living donor liver transplantation

Treatment with Optifast reduces hepatic steatosis and increases candidacy rates for living donor liver transplantation

Computed tomography volume measurements of the liver using a liver segmentation and analysis package: an intra- and inter-rater reliability study

Usefulness of an intra-gastric balloon before bariatric surgery

Contact Info

Product

Resources

About